This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshitomi, Y. Articles by Kuramochi, M. Search for Related Content PubMed PubMed Citation Articles by Yoshitomi, Y. Articles by Kuramochi, M.

Serum Hepatocyte Growth Factor in Patients with Peripheral Arterial Occlusive Disease

Division of Cardiology (Y.Y., Y.M., M.Y., T.S., M.K.), Department of Clinical Research (S.K.), Division of Cardiovascular Surgery (T.U., K.K.), Tohsei National Hospital, Shizuoka 411, Japan

Address all correspondence and requests for reprints to: Yuji Yoshitomi, M.D., Division of Cardiology, Tohsei National Hospital, 762–1 Nagasawa, Shimizu-cho, Suntoh-gun, Shizuoka 411, Japan. E-mail: yyoshito{at}jun.ncvc.go.jp

Hepatocyte growth factor (HGF) is a multifunctional protein implicated in tissue regeneration, wound healing, and angiogenesis. We measured serum HGF concentrations in 37 patients with peripheral arterial occlusive disease (PAOD). Among them, 36 patients underwent arteriography. Serum HGF concentrations were also measured in 40 control subjects who remained free of vascular, liver, kidney, or lung disease. Patients with PAOD showed elevated serum HGF concentrations compared with control subjects (0.40 ± 0.02 vs. 0.19 ± 0.01 ng/mL; P < 0.001). Serum HGF concentrations were significantly higher in smokers compared with nonsmokers (0.45 ± 0.03 vs. 0.35 ± 0.02 ng/mL; P = 0.003). The serum HGF concentrations in patients with collaterals tended to be higher than those in patients without collaterals (0.43 ± 0.03 vs. 0.35 ± 0.02 ng/mL; P = 0.06). Moreover, in patients who underwent bypass surgery or angioplasty, serum HGF concentrations decreased from 0.41 ± 0.03 to 0.21 ± 0.04 ng/mL after treatment (P < 0.001). Serum HGF may be an useful marker for the diagnosis of PAOD. HGF may play an important role in angiogenesis and collateral vessel growth in PAOD.

This article has been cited by other articles:

				J.-W. Lin, W. H.-H. Sheu, W.-J. Lee, Y.-T. Chen, T.-J. Liu, C.-T. Ting, and W.-L. Lee Circulating Hepatocyte Growth Factor Level but Not Basic Fibroblast Growth Factor Level Is Elevated in Angiography-Proven Symptomatic Peripheral Artery Disease Angiology, September 1, 2007; 58(4): 420 - 428. [Abstract] [PDF]

				L. N. Bell, J. L. Ward, M. Degawa-Yamauchi, J. E. Bovenkerk, R. Jones, B. M. Cacucci, C. E. Gupta, C. Sheridan, K. Sheridan, S. S. Shankar, et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E843 - E848. [Abstract] [Full Text] [PDF]

				T. Ohnishi, K. Kakimoto, K. Bandow, C. J. Lowenstein, Y. Daikuhara, and T. Matsuguchi Mature Hepatocyte Growth Factor/Scatter Factor on the Surface of Human Granulocytes Is Released by a Mechanism Involving Activated Factor Xa. J. Immunol., June 1, 2006; 176(11): 6945 - 6953. [Abstract] [Full Text] [PDF]

				P. Palange, U. Testa, A. Huertas, L. Calabro, R. Antonucci, E. Petrucci, E. Pelosi, L. Pasquini, A. Satta, G. Morici, et al. Circulating haemopoietic and endothelial progenitor cells are decreased in COPD. Eur. Respir. J., March 1, 2006; 27(3): 529 - 541. [Abstract] [Full Text] [PDF]

				S. Susen, K. Sautiere, F. Mouquet, F. Cuilleret, A. Chmait, E. P. McFadden, B. Hennache, F. Richard, P. de Groote, J.-M. Lablanche, et al. Serum hepatocyte growth factor levels predict long-term clinical outcome after percutaneous coronary revascularization Eur. Heart J., November 2, 2005; 26(22): 2387 - 2395. [Abstract] [Full Text] [PDF]

				R. Morishita, M. Aoki, N. Hashiya, H. Makino, K. Yamasaki, J. Azuma, Y. Sawa, H. Matsuda, Y. Kaneda, and T. Ogihara Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease Hypertension, August 1, 2004; 44(2): 203 - 209. [Abstract] [Full Text] [PDF]

				J. Rehman, R. V. Considine, J. E. Bovenkerk, J. Li, C. A. Slavens, R. M. Jones, and K. L. March Obesity is associated with increased levels of circulating hepatocyte growth factor J. Am. Coll. Cardiol., April 16, 2003; 41(8): 1408 - 1413. [Abstract] [Full Text] [PDF]